|
2013 Conference Publication Upstream MAPK pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patientsGoldinger, Simone M., Murer, Carla, Stieger, Pascale and Dummer, Reinhard (2013). Upstream MAPK pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, May 31-Jun 04, 2013. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2013 Conference Publication The genetic landscape of clinical resistance to RAF inhibition in melanomaVan Allen, Eliezer Mendel, Wagle, Nikhil, Carter, Scott L., Sucker, Antje, Farlow, Deborah Norman, Hodis, Fran, Taylor-Weiner, Amara, Berking, Carola, Egberts, Friederike, Hassel, Jessica Cecile, Gogas, Helen, Gutzmer, Ralf, Goldinger, Simone M., Loquai, Carmen, Ugurel, Selma, Zimmer, Lisa, Gabriel, Stacey B., Getz, Gad, Garraway, Levi A. and Schadendorf, Dirk (2013). The genetic landscape of clinical resistance to RAF inhibition in melanoma. 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, May 31-Jun 04, 2013. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2013 Conference Publication Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: Association with overall survival?Mangana, Joanna, Goldinger, Simone M., Schindler, Katja, Rozati, Sima, Frauchiger, Anna L., Rechsteiner, Markus, Moch, Holger, Romano, Emanuela, Kaehler, Katharina C., Michielin, Olivier, Hauschild, Axel, Hoeller, Christoph and Dummer, Reinhard (2013). Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: Association with overall survival?. 49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, May 31-Jun 04, 2013. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. |
|
2013 Conference Publication The price of tumor control: An analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab networkHeinzerling, L., Goldinger, S. M., Voskens, C. J., Loquai, C., Robert, C., Berking, C., Eigentler, T., Fluck, M., Garbe, C., Gutzmer, R., Gleiss, H., Hauschild, A., Hein, R., Justich, A., Keller, U., Klein, C., Mateus, C., Mohr, P., Paetzold, S., Satzger, , Schadendorf, D., Schlaeppi, M., Ulrich, J., Vaubel, J., von Moos, R., Weder, P., Wilhelm, T., Kaehler, K., Goeppner, D. ... Schuler, G. (2013). The price of tumor control: An analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. HOBOKEN: WILEY-BLACKWELL. |
|
2013 Journal Article Current treatment of melanoma of the skin = Aktuelle therapie des melanoms der hautDummer, Reinhard, Goldinger, Simone M., Sailer, Eva and French, Lars E. (2013). Current treatment of melanoma of the skin = Aktuelle therapie des melanoms der haut. Therapeutische Umschau, 67 (9), 447-452. doi: 10.1024/0040-5930/a000078 |
|
2013 Journal Article RASopathic Skin Eruptions during Vemurafenib TherapyRinderknecht, Jeannine D., Goldinger, Simone M., Rozati, Sima, Kamarashev, Jivko, Kerl, Katrin, French, Lars E., Dummer, Reinhard and Belloni, Benedetta (2013). RASopathic Skin Eruptions during Vemurafenib Therapy. Plos One, 8 (3) e58721. doi: 10.1371/journal.pone.0058721 |
|
2013 Journal Article Melanoma immunotherapy: historical precedents, recent successes and future prospectsRaaijmakers, Marieke I. G., Rozati, Sima, Goldinger, Simone M., Widmer, Daniel S., Dummer, Reinhard and Levesque, Mitchell P. (2013). Melanoma immunotherapy: historical precedents, recent successes and future prospects. Immunotherapy, 5 (2), 169-182. doi: 10.2217/IMT.12.162 |
|
2013 Journal Article The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab NetworkVoskens, Caroline J., Goldinger, Simone M., Loquai, Carmen, Robert, Caroline, Kaehler, Katharina C., Berking, Carola, Bergmann, Tanja, Bockmeyer, Clemens L., Eigentler, Thomas, Fluck, Michael, Garbe, Claus, Gutzmer, Ralf, Grabbe, Stephan, Hauschild, Axel, Hein, Ruediger, Hundorfean, Gheorghe, Justich, Armin, Keller, Ullrich, Klein, Christina, Mateus, Christine, Mohr, Peter, Paetzold, Sylvie, Satzger, Imke, Schadendorf, Dirk, Schlaeppi, Marc, Schuler, Gerold, Schuler-Thurner, Beatrice, Trefzer, Uwe, Ulrich, Jens ... Heinzerling, Lucie M. (2013). The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network. Plos One, 8 (1) e53745. doi: 10.1371/journal.pone.0053745 |
|
2012 Journal Article Therapeutic approaches in melanoma - A paradigm for personalized medicine = Melanomtherapie - Ein paradigma für die personalized medicineDummer, Reinhard, Goldinger, Simone, Rinderknecht, J., Eggmann, N., Felderer, L., Braun, R. and French, L. E. (2012). Therapeutic approaches in melanoma - A paradigm for personalized medicine = Melanomtherapie - Ein paradigma für die personalized medicine. Praxis, 101 (15), 955-959. doi: 10.1024/1661-8157/a001005 |
|
2012 Journal Article Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8<SUP>+</SUP> T-cell responses in melanoma patientsGoldinger, Simone M., Dummer, Reinhard, Baumgaertner, Petra, Mihic-Probst, Daniela, Schwarz, Katrin, Hammann-Haenni, Anya, Willers, Joerg, Geldhof, Christine, Prior, John O., Kuendig, Thomas M., Michielin, Olivier, Bachmann, Martin F. and Speiser, Daniel E. (2012). Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8+ T-cell responses in melanoma patients. European Journal of Immunology, 42 (11), 3049-3061. doi: 10.1002/eji.201142361 |
|
2012 Journal Article From chemotherapy to targeted treatmentDummer, R., Rozati, S., Eggmann, N., Rinderknecht, J. and Goldinger, S. M. (2012). From chemotherapy to targeted treatment. Annals of Oncology, 23, 101-103. doi: 10.1093/annonc/mds308 |
|
2012 Conference Publication OPEN-LABEL PILOT STUDY OF VEMURAFENIB IN PREVIOUSLY TREATED METASTATIC MELANOMA (MM) PATIENTS (PTS) WITH SYMPTOMATIC BRAIN METASTASES (BM)Dummer, R., Goldinger, S., Turtschi, C., Eggmann, N., Michielin, O., Mitchell, L., Veronese, L., Hilfiker, P. R. and Rinderknecht, J. D. (2012). OPEN-LABEL PILOT STUDY OF VEMURAFENIB IN PREVIOUSLY TREATED METASTATIC MELANOMA (MM) PATIENTS (PTS) WITH SYMPTOMATIC BRAIN METASTASES (BM). 37th Congress of the European-Society-for-Medical-Oncology (ESMO), Vienna Austria, Sep 28-Oct 02, 2012. OXFORD: OXFORD UNIV PRESS. |
|
2012 Journal Article Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective <i>BRAF</i> InhibitionZimmer, Lisa, Hillen, Uwe, Livingstone, Elisabeth, Lacouture, Mario E., Busam, Klaus, Carvajal, Richard D., Egberts, Friederike, Hauschild, Axel, Kashani-Sabet, Mohammed, Goldinger, Simone M., Dummer, Reinhard, Long, Georgina V., McArthur, Grant, Scherag, Andre, Sucker, Antje and Schadendorf, Dirk (2012). Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition. Journal of Clinical Oncology, 30 (19), 2375-2383. doi: 10.1200/JCO.2011.41.1660 |
|
2012 Conference Publication Cutaneous side effects (cAE) of vemurafenib (V): Single-center cohort study of 28 metastatic melanoma (mM) patients (pts)Goldinger, Simone M., Rinderknecht, Jeannine Desiree, Belloni, Benedetta, Eggmann, Nina and Dummer, Reinhard (2012). Cutaneous side effects (cAE) of vemurafenib (V): Single-center cohort study of 28 metastatic melanoma (mM) patients (pts). 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 01-06, 2012. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. |
|
2012 Book Chapter Cutaneous drug eruptions associated with the use of new oncological drugsBelloni, Benedetta, Schönewolf, Nicola, Rozati, Sima, Goldinger, Simone M. and Dummer, Reinhard (2012). Cutaneous drug eruptions associated with the use of new oncological drugs. Adverse cutaneous drug eruptions. (pp. 191-202) edited by Lars E. French. Basel, Switzerland: S. Karger. doi: 10.1159/000335632 |
|
2012 Journal Article Cutaneous Lymphomas: Molecular Pathways Leading to New DrugsDummer, Reinhard, Goldinger, Simone M., Cozzio, Antonio, French, Lars E. and Karpova, Maria B. (2012). Cutaneous Lymphomas: Molecular Pathways Leading to New Drugs. Journal of Investigative Dermatology, 132 (3), 517-525. doi: 10.1038/jid.2011.370 |
|
2012 Journal Article Ultraviolet A and Photosensitivity during Vemurafenib TherapyDummer, Reinhard, Rinderknecht, Jeannine and Goldinger, Simone M. (2012). Ultraviolet A and Photosensitivity during Vemurafenib Therapy. New England Journal of Medicine, 366 (5), 480-481. doi: 10.1056/NEJMc1113752 |
|
2012 Journal Article First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07)von Moos, R., Seifert, B., Simcock, M., Goldinger, S. M., Gillessen, S., Ochsenbein, A., Michielin, O., Cathomas, R., Schlaeppi, M., Moch, H., Schraml, P. H., Mjhic-Probst, D., Mamot, C., Schoenewolf, N. and Dummer, R. (2012). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Annals of Oncology, 23 (2), 531-536. doi: 10.1093/annonc/mdr126 |
|
2011 Conference Publication Final results of single-agent phase II study using the inhibitor of purine nucleoside phosphorylase (PNP) in patients suffering from advanced primary cutaneous t-cell lymphomas (CTCL)Dummer, R., Duvic, M., Scarisbrick, J., Olsen, E., Goldinger, S., Hutchinson, K., Geskin, L., Illidge, T., Kim, Y., Giuliano, E. and Elder, J. (2011). Final results of single-agent phase II study using the inhibitor of purine nucleoside phosphorylase (PNP) in patients suffering from advanced primary cutaneous t-cell lymphomas (CTCL). MALDEN: WILEY-BLACKWELL. |
|
2011 Conference Publication Inhibition of the MEK-kinase pathway in advanced melanomaDummer, R., Goldinger, S., Turtschi, C., Gisler, S., Eggmann, N. and Rinderknecht, J. (2011). Inhibition of the MEK-kinase pathway in advanced melanoma. BASEL: KARGER. |
